Skip to main content
TrimSoMoEverything GLP-1, in one place
FDA Regulatory Enforcement Record

ASN-LABS

Has ASN-LABS received an FDA warning letter? Yes. FDA issued a warning letter dated September 9, 2025 concerning products containing retatrutide and semaglutide and tirzepatide.

Letter facts

Letter date
September 9, 2025 (2025-09-09)
Issuing office
Center for Drug Evaluation and Research (CDER)
Recipient type
Telehealth
Products named
compounded retatrutidecompounded semaglutidetirzepatide
Violation categories
Unapproved new drugMisbrandingCompounding outside 503A/503BFalse or misleading claims

Understanding these violation categories

Unapproved new drug

FDA says these products have not been reviewed or approved for safety and effectiveness before being marketed. A warning letter gives the company an opportunity to address the violations.

Misbranding

FDA says the products' labeling, promotion, or directions did not meet federal requirements, such as lacking adequate directions for use or making unsubstantiated claims. A warning letter is FDA's notice of what it believes are significant violations.

Compounding outside 503A/503B

FDA says this pharmacy's compounded products did not meet the conditions that let pharmacies compound drugs without FDA approval. A warning letter is FDA's notice of what it believes are significant violations; the company can respond.

False or misleading claims

FDA says the company made claims regarding product equivalence, safety, or FDA approval that were inaccurate or not supported by evidence. A warning letter notifies the recipient to bring promotions into compliance.

Factual Violation Summary

FDA says compounded retatrutide is an unapproved new drug lacking adequate directions for use and not eligible for 503A/503B exemptions; semaglutide claims implying equivalence to FDA-approved Wegovy and Ozempic are false or misleading, misbranding the products.

Statutory Citations & Specific Allegations

  • unapproved new drugs
  • misbranded drugs
  • false or misleading claims
  • failure to meet 503A/503B conditions

More letters about Retatrutide

Recent FDA warning letters concerning Retatrutide:

Similar violations (Unapproved new drug)

Recent warning letters with related regulatory findings:

Regulatory Compliance & Editorial Standard:

The information on this page is compiled strictly from public regulatory enforcement documents published by the U.S. Food and Drug Administration (FDA) and reflects official government records at the time of issuance.

Regulatory Notice: Addressed establishments may have implemented corrective actions or entered into compliance agreements with regulatory authorities. For subsequent remedial filings or official FDA closeout letters, refer directly to the FDA.gov source link above.